- Raw materials
- Antibacterials
- Indirubin
Indirubin API Manufacturers & Suppliers
0 verified results
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Indirubin | CAS No: 479-41-4 | GMP-certified suppliers
A medication that shows potential in treating chronic myelogenous leukemia and other cancers through protein kinase inhibition, currently under clinical investigation for antineoplastic applications.
Therapeutic categories
Product Snapshot
- Indirubin is an oral small molecule formulation
- It is primarily investigated for use in oncology and inflammatory diseases
- The compound is currently in the investigational stage and has not received FDA or EMA approval
Clinical Overview
Indirubin is currently under clinical investigation, as exemplified by the clinical trial NCT01735864, which evaluates dosage parameters for an ointment formulation containing indigo naturalis extract, a source of indirubin. The clinical indication for indirubin has not been formally specified, but its categorization includes potential application in the treatment of chronic myelogenous leukemia (BCR-ABL positive) and other oncology-related settings, consistent with its profile as a protein kinase inhibitor.
The mechanism of action and detailed pharmacodynamics of indirubin remain to be fully elucidated. However, its role as a protein kinase inhibitor suggests it interferes with intracellular signaling pathways critical for cell proliferation and survival, which may underpin its antineoplastic properties.
Key pharmacokinetic and ADME (absorption, distribution, metabolism, and excretion) parameters for indirubin are not comprehensively characterized in the current literature, reflecting its status as an investigational compound.
Safety and toxicity data are limited, necessitating careful evaluation during clinical development. No marketed pharmaceutical products were identified with indirubin as the active pharmaceutical ingredient. Its use is primarily research-based or within investigational frameworks.
For formulation scientists and sourcing professionals, it is important to consider the purity profile, batch-to-batch consistency, and regulatory compliance when procuring indirubin API. Given its investigational status, sourcing from suppliers with validated quality control systems and documented stability data is critical to support ongoing research and development efforts.
Identification & chemistry
| Generic name | Indirubin |
|---|---|
| Molecule type | Small molecule |
| CAS | 479-41-4 |
| UNII | 1LXW6D3W2Z |
| DrugBank ID | DB12379 |
Pharmacology
Targets
| Target | Organism | Actions |
|---|---|---|
| Cytochrome P450 1A1 | Humans | substrate |
| Aryl hydrocarbon receptor | Humans | agonist |
Formulation & handling
- Indirubin is a small molecule with low water solubility, indicating potential formulation challenges for oral delivery requiring solubilization strategies. This compound is not a peptide or biologic, minimizing concerns related to enzymatic degradation or cold chain requirements. Stability data is limited; appropriate handling under controlled conditions should be ensured during formulation development.
Regulatory status
Indirubin is a type of Antibacterials
Antibacterials, a category of pharmaceutical active pharmaceutical ingredients (APIs), play a crucial role in combating bacterial infections. These APIs are chemical compounds that target and inhibit the growth or kill bacteria, helping to eliminate harmful bacterial pathogens from the body.
Antibacterials are essential for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and more. They are commonly prescribed by healthcare professionals to combat both mild and severe bacterial infections.
Within the category of antibacterials, there are different classes and subclasses of APIs, each with distinct mechanisms of action and target bacteria. Some commonly used antibacterials include penicillins, cephalosporins, tetracyclines, macrolides, and fluoroquinolones. These APIs work by interfering with various aspects of bacterial cellular processes, such as cell wall synthesis, protein synthesis, DNA replication, or enzyme activity.
The development and production of antibacterial APIs require stringent quality control measures to ensure their safety, efficacy, and purity. Pharmaceutical manufacturers must adhere to Good Manufacturing Practices (GMP) and follow rigorous testing protocols to guarantee the quality and consistency of these APIs.
As bacterial resistance to antibiotics continues to be a significant concern, ongoing research and development efforts aim to discover and develop new antibacterial APIs. The evolution of antibacterials plays a crucial role in combating emerging bacterial strains and ensuring effective treatment options for infectious diseases.
In summary, antibacterials are a vital category of pharmaceutical APIs used to treat bacterial infections. They are designed to inhibit or kill bacteria, and their development requires strict adherence to quality control standards. By continually advancing research in this field, scientists and pharmaceutical companies can contribute to the ongoing battle against bacterial infections.
